Latest European Union News

Sarytogan Graphite Limited updates investors on its $5 million capital raising, highlighting regulatory approval delays but confirming near-term funding to advance its key graphite project.

Memphasys Limited’s partner International Technical Legacy has placed an early order for 500 Felix™ cartridges ahead of anticipated CE Mark approval, signalling strong clinic demand and validating the company’s direct-selling strategy in the Middle East.

Telix Pharmaceuticals confirms completion of Part 1 enrolment in its ProstACT Phase 3 trial for prostate cancer, with safety data supporting progression to Part 2 and regulatory approvals secured across multiple countries.

Almonty Industries has marked a pivotal milestone by delivering the first ore to the ROM pad at its Sangdong tungsten mine, signaling the start of commercial mining and a strategic shift in global tungsten supply chains.

Orthocell has lodged a regulatory application to distribute its nerve repair product Remplir™ across the EU and UK, aiming to tap into a $750 million market with approval expected by Q3 2026.

Osmond Resources has reported strong assay results from its third drill hole at the Orión EU Critical Minerals Project, reinforcing the potential for a globally significant deposit of titanium, zirconium, and rare earth elements. The findings support ongoing development plans targeting EU supply chain needs.

Prospech Limited has significantly increased its Jokikangas project tenure in northern Finland, targeting critical minerals like yttrium and niobium amid soaring European prices. The expansion positions the company strongly within a Tier-1 mining jurisdiction as it plans initial exploration activities.

Krakatoa Resources has reported strong visual antimony mineralisation from underground and surface drilling at its Zopkhito project in Georgia, extending the option period by 12 months to advance resource definition and transaction milestones.

Memphasys Limited has restructured its leadership by eliminating the CEO role to back a direct-selling global commercialisation strategy for its Felix™ System, anticipating imminent CE Mark approval to enter the European IVF market.

Altamin Limited has locked in $753,000 through a share placement to cover part of its entitlement offer shortfall, attracting sophisticated investors from the UK and Australia.

Telix Pharmaceuticals has dosed the first patient in the randomized expansion phase of its pivotal ProstACT Global Phase 3 trial for TLX591, targeting advanced prostate cancer. The trial is expanding globally, with regulatory submissions underway in the US and Europe.

Battery Age Minerals has appointed DGWA as its European strategic advisor to advance the Bleiberg Zinc Germanium Project within the EU’s Critical Raw Materials Act framework, initiating high-level engagements across key EU capitals.